Intec Pharma Nominates John Kozarich As Chairman Of Board - Quick Facts

(RTTNews) - Intec Pharma Ltd. (NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary drug delivery platform technology, the Accordion Pill, said that its board of directors has nominated Dr. John Kozarich to act as its chairman.

Dr. Kozarich has nearly 40 years of experience in the biopharmaceutical industry and academia. Since 2007, he has served as Chairman of Ligand Pharmaceuticals, Inc. (LGND), a biopharmaceutical company.

Ligand has partnerships and license agreements with 85 pharmaceutical and biotechnology companies, over 30 of which are accessing Ligand's proprietary drug delivery technology, Captisol.

In addition, Dr. Kozarich serves as the Chairman and President of ActivX Biosciences, which was acquired by Kyorin Pharmaceuticals of Japan in 2004.

He has also served as Vice President at Merck Research Laboratories and was the first head of R&D of Alkermes in the early nineties. In 2014, Dr. Kozarich was named Director of the Year for Companies in Transition by the Corporate Directors Forum for his work at Ligand and ActivX.